Ralf-Dieter Hilgers was nominated as IRDiRC Task Force Member

/in /by

Ralf-Dieter Hilgers has been invited to serve as an IRDiRC Task Force Member to advance progress in the field of Small Population Clinical trials. With this Task Force, the International Rare Disease Consortium aims at delivering 200 new therapies for rare diseaes and at the means to diagnose most rare diseases by 2020. IDeAl has been identified as a key-player in the field of small population clinical trials, and will take part in the task force as a key-member.

Workshop on Design and Analysis
of Experiments in Healthcare

/in /by

In the week 6-10 July 2015, there will be a workshop on Design and Analysis of Experiments in Healthcare at the Isaac Newton Institute, Cambridge, UK. This workshop is a follow-on to the 2011 six-month research programme on Design and Analysis of Experiments at INI, and is partly funded by IDEAL. In due course, there will be information at Isaac Newton Institute about how to apply to participate in this workshop.

Rare Disease Day

/in /by

The Rare Disease Day takes place every year on the last day of February. According to the initiatives website, the main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. It has notably contributed to the advancement of national plans and policies for rare diseases in a number of countries, in Europe as well as world wide.

IBS joint Seminar with IDeAl mentioned in Biometric Bulletin

/in /by

The International Biometric Society IBS mention the joint seminar with IdeAl in its current Biometric Bulletin. The seminar was organized jointly by the IDeAl project and the WBS. The half day workshop on clinical trial methodology featured talks from Stephen Senn, Holger Dette, Bill Rosenberger, Ralf-Dieter Hilgers Gerald Hlavin and Sergey Krasnozhon.

EMA approved a record number of medicines for rare diseases in 2014

/in /by

According to an EMA press release, the European Medicines Agency in 2014 recommended the highest number of orphan drugs for marketing authorisation in a year. 17 out of 82 medicines that were approved in 2014, are inteded for the treatment of rare diseases. The new medicines for rare diseases include the first medicine for the treatment of Duchenne’s Muscular Dystrophy (DMD), and eight new medicines for rare cancer. DMD as well as rare cancers are among those diseases which the IDeAl group intends to study in detail. The increasing number of medicines receiving a recommendation for marketing authority in 2014 emphasizes the importance of the innovative statistical methods for small population groups that are investigated and developed by the IDeAl project.